Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents

·1-min read

(Reuters) -Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years. 

  A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said. 

  The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide. 

  Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above. 

  The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August. 

  (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli) 

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting